Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Interest Expenses (2022 - 2025)

Historic Interest Expenses for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $16.1 million.

  • Phathom Pharmaceuticals' Interest Expenses fell 1285.44% to $16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.3 million, marking a year-over-year increase of 578.67%. This contributed to the annual value of $72.0 million for FY2024, which is 7158.07% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Interest Expenses stood at $16.1 million for Q3 2025, which was down 1285.44% from $17.5 million recorded in Q2 2025.
  • Over the past 5 years, Phathom Pharmaceuticals' Interest Expenses peaked at $18.6 million during Q4 2024, and registered a low of $2.8 million during Q1 2022.
  • Its 4-year average for Interest Expenses is $12.9 million, with a median of $13.0 million in 2023.
  • As far as peak fluctuations go, Phathom Pharmaceuticals' Interest Expenses surged by 23407.03% in 2023, and later crashed by 1285.44% in 2025.
  • Phathom Pharmaceuticals' Interest Expenses (Quarter) stood at $9.6 million in 2022, then surged by 35.69% to $13.0 million in 2023, then surged by 42.7% to $18.6 million in 2024, then dropped by 13.37% to $16.1 million in 2025.
  • Its last three reported values are $16.1 million in Q3 2025, $17.5 million for Q2 2025, and $18.1 million during Q1 2025.